Open AccessPromising effects of 3rd line cyclophosphamide, adriamycin and vincristine ( CAV ) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer
Author(s) -
Jung Sang Ok,
Kim Sun Young,
Kim JuOck,
Jung Sung Soo,
Park Hee Sun,
Moon Jae Young,
Kim Sung Min,
Lee Jeong Eun
Publication year - 2015
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12198
Subject(s) - medicine , ifosfamide , carboplatin , vincristine , cyclophosphamide , chemotherapy , lung cancer , refractory (planetary science) , oncology , cancer research , etoposide , cisplatin , physics , astrobiology
Third and fourth line chemotherapy agents are not helpful in the setting of extensive stage small cell lung cancer ( SCLC ). We describe the case of a 43‐year‐old K orean patient with T4N3M1b extensive stage SCLC who responded remarkably well to treatment and experienced a prolonged progression‐free survival ( PFS ) period following treatment with fourth line ifosfamide and carboplatin after experiencing disease progression with three previous regimens. Additionally, third line cyclophosphamide, doxorubicin (Adriamycin), and vincristine demonstrated long‐term PFS periods.